世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

北米の抗真菌薬市場 2018-2026年

NORTH AMERICA ANTIFUNGAL AGENTS MARKET 2018-2026

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2018年8月US$1,250
シングルユーザ(印刷不可PDF)
78

サマリー

この調査レポートは北米の抗真菌薬市場を分析・予測したInkwood Researchの市場調査報告書です。

Description

KEY FINDINGS

Huge investments made for drug productions, along with the government initiatives related to fungal infections and their treatment are driving growth in the North America antifungal agents market. Over the forecast years of 2018-2026, the market is likely to showcase a CAGR of 2.80%.

MARKET INSIGHTS

Canada and the United States are the major markets analyzed in this report. The US antifungal agents market captured a dominant market share in the year 2017. The country is blessed with the presence of a number of global pharmaceutical giants that are continuously engaged in the development of new and innovative antifungal drugs. Canada too is witnessing a surge in fungal infections and is expected to show a healthy demand for the antifungal agents market.

COMPETITIVE INSIGHTS


Companies like Merck Co, Kramer Laboratories, Novartis, Abbott Laboratories, Johnson & Johnson, GlaxoSmithKline, Astellas Pharma Inc., Baxter, Arbor Pharmaceuticals Inc., Vertex Pharmaceuticals, Sanofi- Aventis, Teva Pharmaceuticals, and Pfizer are competing in this market.



目次

Table of Contents

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. TROPICAL DRUGS MARKET IS THE EMERGING APPLICATION
3.2.2. ASPERGILLOSIS THERAPEUTIC INDICATION IS LEADING THE MARKET
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. POOR HYGIENE HABITS
4.1.2. DEVELOPMENT OF DRUG RESISTANCE
4.2. MARKET RESTRAINTS
4.2.1. ALTERNATE TREATMENT OPTIONS
4.2.2. REGULATORY ATMOSPHERE
4.3. MARKET OPPORTUNITIES
4.3.1. EMERGING PIPELINE OF NEW AND INNOVATIVE ANTIFUNGAL DRUGS
4.3.2. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.3.3. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
4.4. MARKET CHALLENGES
4.4.1. GROWTH AND DEVELOPMENT OF THE GENERIC ANTIFUNGAL DRUGS MARKET
4.4.2. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
4.4.3. RESISTANCE TO DRUGS
4.4.4. RAPIDLY CHANGING TECHNOLOGY
5. MARKET SEGMENTATION
5.1. MARKET BY DRUG TYPES 2018-2026
5.1.1. SYSTEMIC AZOLES
5.1.2. TOPICAL AZOLES
5.1.3. SYSTEMIC POLYENES
5.1.4. TOPICAL POLYENES
5.1.5. SYSTEMIC ECHINOCANDINS
5.1.6. SYSTEMIC ANTIMETABOLICS
5.1.7. OTHER SYSTEMIC
5.1.8. OTHER TOPICAL
5.1.9. OTHER DRUGS TYPES
5.2. MARKET BY THERAPEUTIC INDICATIONS 2018-2026
5.2.1. ASPERGILLOSIS MARKET
5.2.2. DERMATOPHYTOSIS MARKET
5.2.3. CANDIDIASIS MARKET
5.2.4. OTHER THERAPEUTIC INDICATION MARKET
5.3. MARKET BY APPLICATIONS 2018-2026
5.3.1. TOPICAL ANTIFUNGAL AGENTS MARKET
5.3.2. ORAL DRUGS MARKET
5.4. MARKET BY TYPES 2018-2026
5.4.1. PRESCRIPTION
5.4.2. OVER THE COUNTER (OTC)
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. KEY BUYING CRITERIA
6.3. VALUE CHAIN ANALYSIS
6.3.1. MANUFACTURERS
6.3.2. DISTRIBUTORS
6.3.3. RETAILERS
6.3.4. END-USERS
6.4. REGULATORY FRAMEWORK
6.4.1. REGULATION IN NORTH AMERICA
6.5. OPPORTUNITY MATRIX
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES (U.S.)
7.1.2. CANADA
8. COMPANY PROFILES
8.1. COMPETITIVE LANDSCAPE
8.1.1. MARKET SHARE ANALYSIS
8.2. ABBOTT LABORATORIES.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SCOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. ARBOR PHARMACEUTICALS, INC.
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SCOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. BAXTER
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SCOT ANALYSIS
8.4.4. STRATEGIC INITIATIVES
8.5. ASTELLAS PHARMA INC.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SCOT ANALYSIS
8.5.4. STRATEGIC INITIATIVES
8.6. BAYER HEALTHCARE
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SCOT ANALYSIS
8.6.4. STRATEGIC INITIATIVE
8.7. TEVA PHARMACEUTICALS
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. GILEAD
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. GLAXOSMITHKLINE
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. JOHNSON & JOHNSON
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. KRAMER LABORATORIES
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.12. MERCK & CO.
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVES
8.13. NOVARTIS
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVES
8.14. PFIZER
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVES
8.15. SANOFI-AVENTIS
8.15.1. COMPANY OVERVIEW
8.15.2. PRODUCT PORTFOLIO
8.15.3. SCOT ANALYSIS
8.15.4. STRATEGIC INITIATIVE
8.16. VERTEX PHARMACEUTICALS
8.16.1. COMPANY OVERVIEW
8.16.2. PRODUCT PORTFOLIO
8.16.3. SCOT ANALYSIS
8.16.4. STRATEGIC INITIATIVE

TABLE LIST
TABLE 1 NORTH AMERICA ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)
TABLE 2 SKIN LESIONS OCCURRING DUE TO ANTIFUNGAL INFECTION
TABLE 3 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY DRUG TYPES MARKET 2018-2026 ($ MILLION)
TABLE 4 DRUG USES OF TRIAZOLES
TABLE 5 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC AZOLES 2018-2026 ($ MILLION)
TABLE 6 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN TOPICAL AZOLES 2018-2026 ($ MILLION)
TABLE 7 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC POLYENES 2018-2026 ($ MILLION)
TABLE 8 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN TOPICAL POLYENES 2018-2026 ($ MILLION)
TABLE 9 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ECHINOCANDINS 2018-2026 ($ MILLION)
TABLE 10 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ANTIMETABOLICS 2018-2026 ($ MILLION)
TABLE 11 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER SYSTEMIC 2018-2026 ($ MILLION)
TABLE 12 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER TOPICAL 2018-2026 ($ MILLION)
TABLE 13 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER DRUGS TYPES MARKET 2018-2026 ($ MILLION)
TABLE 14 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY THERAPEUTIC INDICATIONS MARKET 2018-2026 ($ MILLION)
TABLE 15 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN ASPERGILLOSIS 2018-2026 ($ MILLION)
TABLE 16 SYMPTOMS IN THE AFFECTED AREA CAUSED BY DERMATOPHYTES
TABLE 17 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN DERMATOPHYTOSIS MARKET 2018-2026 ($ MILLION)
TABLE 18 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 19 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN CANDIDIASIS 2018-2026 ($ MILLION)
TABLE 20 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER THERAPEUTIC INDICATION 2018-2026 ($ MILLION)
TABLE 21 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY APPLICATIONS MARKET 2018-2026 ($ MILLION)
TABLE 22 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 23 ANTIFUNGAL POWDERS AND IT’S EFFECT
TABLE 24 ANTIFUNGAL OINTMENT AND IT’S EFFECT
TABLE 25 ANTIFUNGAL PASTES AND IT’S EFFECT
TABLE 26 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN TOPICAL ANTIFUNGAL AGENTS 2018-2026 ($ MILLION)
TABLE 27 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS
TABLE 28 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN ORAL DRUGS 2018-2026 ($ MILLION)
TABLE 29 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY TYPES 2018-2026 ($ MILLION)
TABLE 30 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN PRESCRIPTION 2018-2026 ($ MILLION)
TABLE 31 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTC 2018-2026 ($ MILLION)
TABLE 32 NORTH AMERICA ANTI-FUNGAL AGENT MARKET 2018-2026 ($ MILLION)
TABLE 33 NORTH AMERICA ANTI-FUNGAL MARKET BY COUNTRIES 2018-2026 ($ MILLION)


FIGURE LIST
FIGURE 1 NORTH AMERICA ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)
FIGURE 2 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 3 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 4 VALUE CHAIN OF ANTIDEPRESSANT DRUGS
FIGURE 5 THE UNITED STATES ANTI-FUNGAL AGENTS MARKET 2018-2026 ($ MILLION)
FIGURE 6 CANADA ANTIFUNGAL AGENT MARKET 2018-2026 ($ MILLION)
FIGURE 7 ANTI-FUNGAL AGENT COMPANY MARKET SHARE ANALYSIS 2017 (%)

List of Tables

TABLE LIST
TABLE 1 NORTH AMERICA ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)
TABLE 2 SKIN LESIONS OCCURRING DUE TO ANTIFUNGAL INFECTION
TABLE 3 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY DRUG TYPES MARKET 2018-2026 ($ MILLION)
TABLE 4 DRUG USES OF TRIAZOLES
TABLE 5 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC AZOLES 2018-2026 ($ MILLION)
TABLE 6 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN TOPICAL AZOLES 2018-2026 ($ MILLION)
TABLE 7 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC POLYENES 2018-2026 ($ MILLION)
TABLE 8 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN TOPICAL POLYENES 2018-2026 ($ MILLION)
TABLE 9 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ECHINOCANDINS 2018-2026 ($ MILLION)
TABLE 10 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ANTIMETABOLICS 2018-2026 ($ MILLION)
TABLE 11 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER SYSTEMIC 2018-2026 ($ MILLION)
TABLE 12 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER TOPICAL 2018-2026 ($ MILLION)
TABLE 13 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER DRUGS TYPES MARKET 2018-2026 ($ MILLION)
TABLE 14 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY THERAPEUTIC INDICATIONS MARKET 2018-2026 ($ MILLION)
TABLE 15 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN ASPERGILLOSIS 2018-2026 ($ MILLION)
TABLE 16 SYMPTOMS IN THE AFFECTED AREA CAUSED BY DERMATOPHYTES
TABLE 17 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN DERMATOPHYTOSIS MARKET 2018-2026 ($ MILLION)
TABLE 18 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 19 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN CANDIDIASIS 2018-2026 ($ MILLION)
TABLE 20 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER THERAPEUTIC INDICATION 2018-2026 ($ MILLION)
TABLE 21 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY APPLICATIONS MARKET 2018-2026 ($ MILLION)
TABLE 22 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 23 ANTIFUNGAL POWDERS AND IT’S EFFECT
TABLE 24 ANTIFUNGAL OINTMENT AND IT’S EFFECT
TABLE 25 ANTIFUNGAL PASTES AND IT’S EFFECT
TABLE 26 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN TOPICAL ANTIFUNGAL AGENTS 2018-2026 ($ MILLION)
TABLE 27 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS
TABLE 28 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN ORAL DRUGS 2018-2026 ($ MILLION)
TABLE 29 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY TYPES 2018-2026 ($ MILLION)
TABLE 30 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN PRESCRIPTION 2018-2026 ($ MILLION)
TABLE 31 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTC 2018-2026 ($ MILLION)
TABLE 32 NORTH AMERICA ANTI-FUNGAL AGENT MARKET 2018-2026 ($ MILLION)
TABLE 33 NORTH AMERICA ANTI-FUNGAL MARKET BY COUNTRIES 2018-2026 ($ MILLION)

Companies Mentioned

1. ABBOTT LABORATORIES.
2. ARBOR PHARMACEUTICALS, INC.
3. BAXTER
4. ASTELLAS PHARMA INC.
5. BAYER HEALTHCARE
6. TEVA PHARMACEUTICALS
7. GILEAD
8. GLAXOSMITHKLINE
9. JOHNSON & JOHNSON
10. KRAMER LABORATORIES
11. MERCK & CO.
12. NOVARTIS
13. PFIZER
14. SANOFI-AVENTIS
15. VERTEX PHARMACEUTICALS

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る